SCV
SGP

Sands Capital Ventures’s SpyGlass Pharma SGP Stock Holding History

Sands Capital Ventures’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.7M Hold
2,500,012
– – 9.07% 5
2026
Q1 		$64.8M Buy
+2,500,012
New +$67.3M 15.38% 3

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sands Capital Ventures's SGP Position: Q2 2026 in Review

Sands Capital Ventures held its SpyGlass Pharma (SGP) position steady in Q2 2026 at 2,500,012 shares worth $55.7M. The position accounts for 9.07% of the portfolio, ranked #5.

Sands Capital Ventures first reported a position in SGP in Q1 2026 and has held it in 2 quarters since. The position peaked at $64.8M in Q1 2026. 43 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • Sands Capital Ventures held 2,500,012 shares of SpyGlass Pharma worth $55.7M as of Q2 2026.
  • Sands Capital Ventures left its SpyGlass Pharma share count unchanged in Q2 2026.
  • SpyGlass Pharma made up 9.07% of Sands Capital Ventures's portfolio in Q2 2026, its #5 holding.
  • Sands Capital Ventures first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 2 quarters since.
  • Sands Capital Ventures's SpyGlass Pharma position peaked at $64.8M in Q1 2026.
  • 43 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on Sands Capital Ventures's 13F filing for Q2 2026, filed 13 Aug 2026.